← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Najit Technologies, Inc.
Portland, OR
$18,140,990
Total funding
10
Grants
Funding over time
peak $2.5M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,916,819 · 9
CDC$224,171 · 1
By mechanism
R44$9,212,812 · 2
U44$5,372,018 · 2
R43$2,463,080 · 3
R41$1,093,080 · 3
Investigators at Najit Technologies, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of a Yellow Fever Vaccine for a Vulnerable Population$1,248,114
R44 · FY2018 · AI
Development of a Yellow Fever Vaccine for Vulnerable Population$999,884
R44 · FY2011 · AI
A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine$999,652
U44 · FY2021 · AI
Development of an H2O2-inactivated chikungunya virus vaccine$999,652
R44 · FY2017 · AI
A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine$997,662
U44 · FY2022 · AI
Development of a Yellow Fever Vaccine for a Vulnerable Population$997,494
R44 · FY2020 · AI
Development of a Yellow Fever Vaccine for a Vulnerable Population$996,895
R44 · FY2019 · AI
Development of an H2O2-inactivated chikungunya virus vaccine$994,841
R44 · FY2018 · AI
Development of a Yellow Fever Vaccine for Vulnerable Population$994,154
R44 · FY2013 · AI
Development of a Yellow Fever Vaccine for Vulnerable Population$992,669
R44 · FY2012 · AI
Development of an H2O2-inactivated chikungunya virus vaccine$989,109
R44 · FY2019 · AI
A Randomized Phase I Clinical Trial of HydroVax-CHIKV, a Novel Inactivated Chikungunya Virus Vaccine$986,133
U44 · FY2024 · AI
A Randomized Phase I Clinical Trial of HydroVax-CHIKV, a Novel Inactivated Chikungunya Virus Vaccine$980,963
U44 · FY2025 · AI
Rapid Diagnosis of Monkeypox and Smallpox Infections$834,712
R43 · FY2008 · AI
A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine$825,048
U44 · FY2023 · AI
Rapid Diagnosis of Monkeypox and Smallpox Infections$818,995
R43 · FY2007 · AI
Rapid Diagnosis of Monkeypox and Smallpox Infections$499,382
R41 · FY2005 · AI
Development of a novel platform to enhance intracellular bioavailability of antisense morpholino oligomers$318,591
R41 · FY2016 · AI
Development of a Yellow Fever Vaccine for Vulnerable Populations$292,941
R43 · FY2008 · AI
Development of a Yellow Fever Vaccine for Vulnerable Populations$292,261
R43 · FY2009 · AI